2 false false false false false false false false false false true false false false false false false No description of principal activity 2024-10-01 Sage Accounts Production Advanced 2023 - FRS102_2023 311,396 311,396 311,396 xbrli:pure xbrli:shares iso4217:GBP 07777000 2024-10-01 2025-09-30 07777000 2025-09-30 07777000 2024-09-30 07777000 2023-10-01 2024-09-30 07777000 2024-09-30 07777000 2023-09-30 07777000 bus:Director1 2024-10-01 2025-09-30 07777000 core:WithinOneYear 2025-09-30 07777000 core:WithinOneYear 2024-09-30 07777000 core:AfterOneYear 2025-09-30 07777000 core:AfterOneYear 2024-09-30 07777000 core:ShareCapital 2025-09-30 07777000 core:ShareCapital 2024-09-30 07777000 core:RetainedEarningsAccumulatedLosses 2025-09-30 07777000 core:RetainedEarningsAccumulatedLosses 2024-09-30 07777000 core:LandBuildings 2025-09-30 07777000 core:LandBuildings 2024-09-30 07777000 bus:Director1 2024-09-30 07777000 bus:Director1 2023-09-30 07777000 bus:SmallEntities 2024-10-01 2025-09-30 07777000 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 07777000 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 07777000 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 07777000 bus:FullAccounts 2024-10-01 2025-09-30
COMPANY REGISTRATION NUMBER: 07777000

Sutton Medical Solutions Limited

Filleted Unaudited Financial Statements

30 September 2025

Sutton Medical Solutions Limited

Statement of Financial Position

30 September 2025

| 2025 | 2024
Note | £ | £ | £

Fixed assets

Tangible assets | 5 |  | 311,396 | 311,396

Current assets

Stocks | 432,693 |  | 432,693
Debtors | 6 | 357,614 |  | 356,531
Investments | 7 | 289,265 |  | 247,575
Cash at bank and in hand | 52,223 |  | 5,108
| ------------ |  | ------------
| 1,131,795 |  | 1,041,907

Creditors: amounts falling due within one year | 8 | 199,445 |  | 152,079
| ------------ |  | ------------
Net current assets |  | 932,350 | 889,828
|  | ------------ | ------------
Total assets less current liabilities |  | 1,243,746 | 1,201,224

Creditors: amounts falling due after more than one year | 9 |  | 348,905 | 344,905
|  | ------------ | ------------
Net assets |  | 894,841 | 856,319
|  | ------------ | ------------

Capital and reserves

Called up share capital |  | 300 | 300
Profit and loss account |  | 894,541 | 856,019
|  | --------- | ---------
Shareholders funds |  | 894,841 | 856,319
|  | --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Sutton Medical Solutions Limited

Statement of Financial Position (continued)

30 September 2025
These financial statements were approved by the board of directors and authorised for issue on 26 June 2026 , and are signed on behalf of the board by:

Dr A Hafeez
Director

Company registration number: 07777000

Sutton Medical Solutions Limited

Notes to the Financial Statements

Year ended 30 September 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 113 Westmead Road, Sutton, Surrey, SM1 4JE.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity. Compound instruments Compound instruments comprise both a liability and an equity component. At date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar debt instrument. The liability component is accounted for as a financial liability. The residual is the difference between the net proceeds of issue and the liability component (at time of issue). The residual is the equity component, which is accounted for as an equity instrument. The interest expense on the liability component is calculated applying the effective interest rate for the liability component of the instrument. The difference between this amount and any repayments is added to the carrying amount of the liability in the balance sheet.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 2 (2024: 2 ).
5. Tangible assets

| Land and buildings
| £
Cost |
At 1 October 2024 and 30 September 2025 | 311,396
| ---------
Depreciation |
At 1 October 2024 and 30 September 2025 | –
| ---------
Carrying amount |
At 30 September 2025 | 311,396
| ---------
At 30 September 2024 | 311,396
| ---------

6. Debtors

| 2025 | 2024
| £ | £
Other debtors | 357,614 | 356,531
| --------- | ---------

7. Investments

| 2025 | 2024
| £ | £
Other investments - FPP | 294,265 | 252,575
Other investments - ANA Property Investments Ltd | (5,000) | (5,000)
| --------- | ---------
| 289,265 | 247,575
| --------- | ---------

8. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Corporation tax | 11,368 | 13,747
Medleg Doctors Limited | 188,077 | 138,077
Other creditors | – | 255
| --------- | ---------
| 199,445 | 152,079
| --------- | ---------

9. Creditors: amounts falling due after more than one year

| 2025 | 2024
| £ | £
Other creditors | 348,905 | 344,905
| --------- | ---------

10. Directors' advances, credits and guarantees
During the year the directors entered into the following advances and credits with the company:

| Balance brought forward and outstanding
| 2025 | 2024
| £ | £
Dr A Hafeez | 1,083 | ( 255)
| ------- | ----

11. Related party transactions
The company was under the control of Dr Amer Hafeez and Mrs Naomi Hafeez throughout the year. Dr A Hafeez and Mrs N Hafeez are the managing directors and majority shareholders. Included in other debtors is £245,000.00 (2024 - £245,000.00) owed by Blue Ocean Residency Limited. Dr. A Hafeez is a director and Shareholder in Blue Ocean Residency Limited. Included in investments is £294,264.50 (2024 - £252,574.50) owed by friends property portfolio limited. Dr A Hafeez is a director and shareholder in Friends Property Portfolio Limited. Included in investments is £5,000 (2024 - £5,000.00) owed to ANA Property Investments Ltd. Dr A Hafeez is a director and shareholder in ANA Property Investments Ltd. Included in other creditors is £218,410.00 (2024 - £214,410.00) owed to Harley Medical Solutions Ltd. Dr A Hafeez and Mrs N Hafeez are the managing directors and majority shareholders in Harley Medical Solutions Ltd. Included in other creditors is £188,075.98 (2024 - £138,075.98) owed to Medleg Doctors Limited. Dr A Hafeez is a director and shareholder in Medleg Doctors Limited. Included in other creditors is £127,994.54 (2024 - £127,994.54) owed to Grip Technologies Ltd. Dr A Hafeez is a shareholder in Grip Technologies Ltd. Included in other creditors is £2,500.00 (2024 - £2,500.00) owed to KA Property Portfolio Ltd. Dr A Hafeez is a director and shareholder in KA Property Portfolio Ltd. Included in the closing stock is the company's share of properties held under trust on its behalf.